TY - JOUR
AU - Healy, Daniel P
AB - 3. Worobec SM, Wong FA, Tolman EL, Abrams LS, Parker GR, Thorne the National System of Pharmacovigilance. After evaluation, ANMAT EG. Percutaneous absorption of H-tretinoin in normal volunteers (ab- has recommended inclusion of night or sleep terror as an adverse effect stract). J Invest Dermatol 1991;96:574A. of oxybutynin in all package inserts of products containing the drug sold 4. Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital in Argentina. Considering our findings, we alert practitioners regarding disorders. Lancet 1993;341:1181-2. the use of oxybutynin, mainly in children and the elderly, who have a 5. Frantz TJ, Lehman PA. Systemic absorption of retinoic acid. J Toxicol greater tendency to develop central nervous system adverse drug reac- Cutan Ocul 1990;9:517-24. tions. 6. Kawashima H, Ohno I, Ueno Y, Nakaya S, Kalo E, Taniguchi N. Syn- MABEL E VALSECIA DDS drome of microtia and aortic arch anomalies resembling isotretinoin em- Assistant Professor of Pharmacology bryopathy. J Pediatr 1987;111:738-40. and 7. Kwasigroch TE, Bullen M. Effects of isotretinoin (13-cis-retinoic acid) Chief on the development of mouse limbs in vivo and in vitro. Teratology Regional Pharmacovigilance Center 1991;44:605-16. National Northeast University School of Medicine 8. Camera G, Pregliasco P. Ear malformation 
TI - Correction: Reduced Tetracycline Bioavailability Caused by Magnesium Aluminum Silicate in Liquid Formulations of Bismuth Subsalicylate
JF - Annals of Pharmacotherapy
DO - 10.1177/106002809803200401
DA - 1998-04-01
UR - https://www.deepdyve.com/lp/sage/correction-reduced-tetracycline-bioavailability-caused-by-magnesium-dnJac28Pi4
SP - 506
EP - 506
VL - 32
IS - 4
DP - DeepDyve
ER -